Latest news and upcoming events
Multi-center Clinical Study Data on Anaconda Biomed’s Mechanical Thrombectomy System Published in Stroke
ANA System Shown to Achieve High Rate of Complete Recanalization, Favorable 90 Day Outcomes
SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022
Sparingvisionill be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
AU-011 was previously granted Orphan Drug Designation for the treatment of uveal melanoma by the U.S. Food and Drug Administration.
CorWave to set up its manufacturing facility and expand to a new site next to Paris
The industrial start-up is preparing to move to larger premises capable of hosting its R&D center and the manufacturing facility needed to enter the clinical and commercial phases.
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
The program will include an overview of choroidal melanoma (CM), AU-011’s novel mechanism of action.
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
The recording will be available following the conference under the "Events" tab on the investor relations section of the LAVA Therapeutics
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives
Lava Therapeutics presents initial LAVA-051 clinical data at the ESMO Targeted Anticancer Therapies Congress 2022
LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.